Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque Psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Kim A. Papp, James G. Krueger, Steven R. Feldman, Richard G. Langley, Diamant Thaci, Hideshi Torii, Stephen Tyring, Robert Wolk, Annie Gardner, Charles Mebus, Huaming Tan, Yingchun Luo, Pankaj Gupta, Lotus Mallbris, Svitlana Tatulych*

*Corresponding author for this work
40 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque Psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study'. Together they form a unique fingerprint.

Medicine & Life Sciences